When aggressive LDL targets (< 55 mg/dL) for high-risk patients with history of TIA or stroke cannot be attained with statin therapy alone, the addition of ezetimibe and/or PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors is recommended [21, 63]. The gene discussed is PCSK9; the disease is transient ischemic attack.